JAMA dermatology最新文献

{"title":"Giant Plexiform Neurofibroma in Neurofibromatosis Type 1.","authors":"Yusuf Demir, Fatma Zehra Diken, Burhan Engin","doi":"10.1001/jamadermatol.2026.3150","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3150","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome.","authors":"Laura B Pincus, Weiyun Z Ai","doi":"10.1001/jamadermatol.2026.3855","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3855","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCMA-Targeted T-Cell Engager Therapy for Refractory Pemphigus.","authors":"Moritz Ronicke, Tobias Rothe, Fabian Müller, Carola Berking, Georg Schett, Ricardo Grieshaber-Bouyer, Michael Sticherling","doi":"10.1001/jamadermatol.2026.3051","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3051","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generalized Linear Keratotic Papules in a Man in His 30s.","authors":"Jiaping Zhu, Jianfang Sun","doi":"10.1001/jamadermatol.2026.2792","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.2792","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudofolliculitis Barbae Diagnosis and Treatment in US Veterans.","authors":"Courtney A Smith, Olivia Collins, Chiagoziem Ohamadike, Howa Yeung","doi":"10.1001/jamadermatol.2026.3777","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3777","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13628394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Growth in Children With Epidermal Differentiation Disorders.","authors":"Caroline Echeandia-Francis, Angela J Luo, William Liu, Mitra V Mani, Tiffany X Chen, Emily Sirotich, Riddhi D Patel, Lidia Ossowska, Geliang Gan, Yanhong Deng, Amy S Paller, Keith A Choate","doi":"10.1001/jamadermatol.2026.3782","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3782","url":null,"abstract":"<p><strong>Importance: </strong>Children with epidermal differentiation disorders (EDDs) frequently exhibit impaired growth, yet longitudinal growth trajectories across multiple EDD genotypes have not been systematically evaluated.</p><p><strong>Objective: </strong>To characterize longitudinal growth outcomes, including height, weight, and head circumference, in children with EDDs and evaluate genotype-specific associations.</p><p><strong>Design, setting, and participants: </strong>This longitudinal cohort study of children with EDDs used registry-based survey data and pediatric growth measurements through age 18 years. Data were collected from June 2022 to June 2025 and analyzed in September 2025. Participants were recruited through the National Registry for Ichthyosis; growth data were analyzed using US Centers for Disease Control and Prevention/World Health Organization pediatric growth standards. A total of 135 individuals aged 30 years or younger from 129 kindreds with confirmed EDDs and 26 unaffected siblings from 20 kindreds were included. Participants were classified into 5 genotype-based groups: autosomal recessive nonsyndromic-EDDs (nEDD), SPINK5-syndromic EDD (sEDD), keratinopathic-nEDDs, FLG-nEDD, and STS-sEDD.</p><p><strong>Exposures: </strong>The primary exposure was EDD genotype. Secondary exposures included supplemental caloric intake, gastrostomy tube use, preterm birth, and neonatal intensive care unit admission.</p><p><strong>Main outcomes and measures: </strong>Primary outcomes were longitudinal height, weight, and head circumference percentiles from birth to age 18 years. Growth trajectories were analyzed using linear mixed-effects models, comparing EDD subtypes with population norms at monthly points within prespecified age intervals (age 0-24, 25-48, and >48 months).</p><p><strong>Results: </strong>Among 135 participants (62 female [45.9%] and 73 male individuals [54.1%]; mean [SD] age, 10.5 [6.8] years; 13 Asian [9.6%], 7 Black [5.2%], 9 Hispanic [6.7%], and 89 White individuals [65.9%]), mean weight and height were less than the 50th percentile during the first 24 months of life (weight, 31.4th percentile; P < .001; height, 39.0th percentile; P = .02), with no significant difference from the population median thereafter. Growth impairment depended on genotype: individuals with SPINK5 variants exhibited persistent deficits at age 25 to 48 months (weight, 17.7th percentile; P = .002; height, 6.8th percentile; P < .001), whereas early deficits associated with ABCA12 and KRT10 variants attenuated over time and were no longer statistically significant.</p><p><strong>Conclusions and relevance: </strong>The results of this cohort study suggest that growth impairment in EDDs depends on genotype and is most prominent during the earliest months of life. Routine growth monitoring should be standard of care, particularly for children with high-risk genotypes, such as SPINK5.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13628388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement.","authors":"Yagiz Matthew Akiska, Jennifer Fu, Leslie Castelo-Soccio, Erin Mathes, Paradi Mirmirani, Taylor Jamerson, Cathryn Sibbald, Leonardo Spagnol Abraham, Asim Ali, Lisa M Arkin, Leila Asfour, Karyn Austin, Bevin Bhoyrul, Maria Gnarra Buethe, Valerie D Callender, Carol E Cheng, Vijaya Chitreddy, Megan Craddock, William Cranwell, Brittany G Craiglow, Nisha S Desai, Isabella Doche, Bruna Duque-Estrada, Samantha Eisman, Adam Friedman, Aniza Giacaman, Maria Hordinsky, Ali Jabbari, Han Byul Kang, Brett King, Daniella Kushnir-Grinbaum, Natasha Mesinkovska, Ilka Arun Netravali, Michelle Oboite, Elise A Olsen, Seth J Orlow, Vikash S Oza, Yuliya Ovcharenko, Amy Paller, Shivani Patel, Melissa Piliang, Rodrigo Pirmez, Adriana Rakowska, Paulo Müller-Ramos, David Saceda-Corralo, Kimberly S Salkey, Fernanda Bellodi Schmidt, Rodney Sinclair, Kristen Lo Sicco, Jennifer Soung, Meredith Steuer, Maryanne Makredes Senna, Michelle Tarbox, Antonella Tosti, Jackson Turbeville, Dmitri Wall","doi":"10.1001/jamadermatol.2026.3749","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3749","url":null,"abstract":"<p><strong>Importance: </strong>Low-dose oral minoxidil (LDOM) is increasingly used off-label to treat pediatric hair disorders; however, standardized guidance for patient selection, dosing, safety, and monitoring in patients younger than 12 years is lacking.</p><p><strong>Objective: </strong>To establish expert consensus recommendations for LDOM use in pediatric patients (age <12 years) with hair disorders.</p><p><strong>Evidence review: </strong>Survey development was informed by a review of the literature on LDOM pharmacology, safety, and clinical use, with emphasis on pediatric populations. A modified Delphi process was conducted from June 30, 2025, to March 7, 2026. Of 98 clinicians completing a prescreening survey, 51 met eligibility criteria (>10 pediatric patients treated with LDOM) and were invited to participate. Three iterative survey rounds were conducted using REDCap with multidisciplinary input. Consensus was defined as 70% or greater agreement on a 5-point Likert scale.</p><p><strong>Findings: </strong>Of 51 experts, 50 from 9 countries completed rounds 1 and 2, and 49 (98.0% retention rate) completed round 3, reflecting broad international representation. Of 127 initial items considered, 84 achieved consensus. LDOM is supported for pediatric patients (aged ≥4 to <12 years) for hair follicle miniaturization (100%), hair cycle abnormalities (100%), and hair shaft disorders (84%), with adjunctive use in select scarring alopecia (98%). Preference for LDOM over topical minoxidil included concerns for logistical difficulty, poor tolerability, inadequate efficacy, caregiver preference, diffuse hair loss, sensory sensitivities, or risk of toxic effects in domestic animals (pets) (74%-96%). Both fixed weight-based and mg/kg dosing strategies met consensus. Fixed dosing aligned with available tablet formulations (weight <20 kg, 0.250-0.625 mg; 20-40 kg, 1.250 mg; >40 kg, 1.875 mg [ 80%]), while a starting dosage of 0.01 to 0.02 mg/kg/d (73.5%) provided a flexible alternative. Dosage escalation of 50% to 100% and reassessment every 3 to 6 months reached consensus. Contraindications included pericardial effusion or tamponade and pheochromocytoma. For experts, routine baseline testing and blood pressure monitoring were not universally necessary in patients at low risk. LDOM was supported as long-term therapy with tapering strategies, and as combination therapy with additional agents (eg, spironolactone, corticosteroids, Janus kinase inhibitors, and other immunosuppressants) as appropriate for subtype of hair loss.</p><p><strong>Conclusions and relevance: </strong>This international consensus statement provides a structured, pediatric-specific framework for LDOM use, supporting it as a flexible, nonimmunosuppressive therapeutic strategy and addressing key gaps in dosing, safety, and monitoring.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial.","authors":"Aaron R Mangold, Benjamin Lockshin, Zhihong Lai, Rong Rong, Haq Nawaz, Benjamin D Ehst","doi":"10.1001/jamadermatol.2026.3646","DOIUrl":"10.1001/jamadermatol.2026.3646","url":null,"abstract":"<p><strong>Importance: </strong>Lichen planus is a chronic, highly pruritic, inflammatory disease that affects the skin and other tissues.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of ruxolitinib, 1.5%, cream in patients with cutaneous lichen planus.</p><p><strong>Design, setting, and participants: </strong>This phase 2, 16-week, randomized, double-blind, vehicle-controlled trial with a 16-week open-label extension was conducted from November 2022 to February 2024. Patients were enrolled from 19 sites in the US and Canada. The trial included adults with predominantly cutaneous lichen planus, an Investigator's Global Assessment (IGA) score of 3 or 4, an Itch Numerical Rating Scale score of 4 or greater, and an affected body surface area of 20% or less were enrolled. Data were analyzed from February to August 2024.</p><p><strong>Interventions: </strong>Patients were randomized 1:1 to ruxolitinib, 1.5%, twice daily cream or vehicle cream for 16 weeks, after which eligible patients applied ruxolitinib cream twice daily as needed in a 16-week, open-label extension.</p><p><strong>Main outcomes and measures: </strong>The primary end point was IGA treatment success (IGA score of 0 or 1 [clear/almost clear skin] with a ≥2-grade improvement from baseline) at week 16.</p><p><strong>Results: </strong>Among 64 randomized patients, 46 (72%) were female, 18 (28%) were male, 18 (28%) were African American/Black, 4 (6%) were Asian, 40 (63%) were White, and the median (range) age was 57.0 (18-78) years. Significantly more patients who applied ruxolitinib, 1.5%, cream vs vehicle achieved IGA treatment success (50.0% [95% CI, 31.9%-68.1%] vs 21.9% [95% CI, 9.3%-40.0%], respectively; response rate difference, 29.4% [95% CI, 7.6%-51.3%]; P = .01; primary end point) at week 16, with further improvement to week 32. Similar results were observed in the proportion of patients who achieved a 4 or greater-point improvement from baseline in Itch Numerical Rating Scale score (week 16, 48.4% [95% CI, 30.2%-66.9%] vs 16.1% [95% CI, 5.5%-33.7%]; response rate difference, 33.5%; 95% CI, 12.2%-54.9%; P = .004; secondary end point). No serious treatment-emergent adverse events or discontinuations due to an adverse event were observed with ruxolitinib cream.</p><p><strong>Conclusions and relevance: </strong>The results of this randomized clinical trial suggest that ruxolitinib cream significantly reduced lesions and itch in patients with lichen planus. Therefore, ruxolitinib cream represents a potential treatment option for patients with cutaneous lichen planus.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05593432.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Permanent Hair Removal as Medically Necessary Gender-Affirming Care-Beyond the Cosmetic Label.","authors":"Gabriela Olmedo, Alexandr Trifonov, Gwendolyn P Quinn","doi":"10.1001/jamadermatol.2026.3688","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3688","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply.","authors":"April W Armstrong, Yvonne Nong, Joseph F Merola","doi":"10.1001/jamadermatol.2026.3645","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.3645","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}